MX2009005368A - Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina. - Google Patents

Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.

Info

Publication number
MX2009005368A
MX2009005368A MX2009005368A MX2009005368A MX2009005368A MX 2009005368 A MX2009005368 A MX 2009005368A MX 2009005368 A MX2009005368 A MX 2009005368A MX 2009005368 A MX2009005368 A MX 2009005368A MX 2009005368 A MX2009005368 A MX 2009005368A
Authority
MX
Mexico
Prior art keywords
formulation containing
parenteral formulation
benzodiazepine structure
stable parenteral
rsv inhibitor
Prior art date
Application number
MX2009005368A
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Wei-Qin Tong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009005368A publication Critical patent/MX2009005368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de compuesto de benzodiazepina, las cuales son activas contra el virus sincicial respiratorio (RSV) adecuadas para administración parenteral.
MX2009005368A 2006-11-21 2007-11-20 Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina. MX2009005368A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86664606P 2006-11-21 2006-11-21
PCT/US2007/024246 WO2008063634A1 (en) 2006-11-21 2007-11-20 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure

Publications (1)

Publication Number Publication Date
MX2009005368A true MX2009005368A (es) 2009-06-05

Family

ID=39156434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005368A MX2009005368A (es) 2006-11-21 2007-11-20 Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.

Country Status (16)

Country Link
US (1) US20100056500A1 (es)
EP (1) EP2094308B1 (es)
JP (1) JP2010510311A (es)
KR (1) KR20090087079A (es)
CN (1) CN101553258A (es)
AT (1) ATE494896T1 (es)
AU (1) AU2007321977A1 (es)
BR (1) BRPI0719096A2 (es)
CA (1) CA2669705A1 (es)
DE (1) DE602007011973D1 (es)
ES (1) ES2359856T3 (es)
MX (1) MX2009005368A (es)
PL (1) PL2094308T3 (es)
PT (1) PT2094308E (es)
RU (1) RU2009123536A (es)
WO (1) WO2008063634A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2611995T3 (es) * 2007-01-19 2017-05-11 Hananja Ehf Métodos y composiciones para el suministro de un agente terapéutico
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN101677956A (zh) * 2007-06-11 2010-03-24 阿普尔顿纸张公司 包含有益剂的递送颗粒
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
CA2807528C (en) * 2010-08-05 2018-09-25 Siga Technologies, Inc. St-246 liquid formulations and methods
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
CN117355311A (zh) 2022-05-05 2024-01-05 阿卜杜拉·库尔卡耶夫 用于恢复生物体生理过程和细胞的药物组合物
EP4356925A3 (en) * 2022-10-18 2024-05-01 Takeda Vaccines, Inc. Dengue vaccine formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JP2003522207A (ja) * 1998-02-23 2003-07-22 サイクロプス・イーエイチエフ 高エネルギーシクロデキストリン複合体
EE200100382A (et) * 1999-01-21 2002-12-16 Bristol-Myers Squibb Company Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod
BR0314595A (pt) * 2002-09-20 2005-08-09 Arrow Therapeutics Ltd Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds

Also Published As

Publication number Publication date
CN101553258A (zh) 2009-10-07
WO2008063634A1 (en) 2008-05-29
EP2094308A1 (en) 2009-09-02
PL2094308T3 (pl) 2011-06-30
JP2010510311A (ja) 2010-04-02
ATE494896T1 (de) 2011-01-15
ES2359856T3 (es) 2011-05-27
PT2094308E (pt) 2011-04-14
US20100056500A1 (en) 2010-03-04
KR20090087079A (ko) 2009-08-14
BRPI0719096A2 (pt) 2013-12-03
EP2094308B1 (en) 2011-01-12
AU2007321977A1 (en) 2008-05-29
DE602007011973D1 (de) 2011-02-24
RU2009123536A (ru) 2010-12-27
CA2669705A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
PL2094308T3 (pl) Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
HK1076605A1 (en) Formulations
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
WO2009115178A3 (de) Gingival-wafer
MY148634A (en) Pyridazinone derivatives
PL1834635T3 (pl) Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
WO2007087548A3 (en) Chemical compounds
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MX2010004232A (es) Compuesto de indolina de pirimidilo.
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
TW200517106A (en) Sustained release pharmaceutical compositions
TW200806291A (en) Pharmaceutical formulations
MY163762A (en) Therapeutic agent for chronic renal failure
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
WO2008074833A3 (en) Compounds
MX2007015171A (es) Formulacion que comprende farnesil dibenzodiazepinona y un tensoactivo farmaceuticamente aceptable.
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
EP2101742B8 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal